Floatz logo

Iparomlimab

Acral Melanoma

Fudan UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the Acral Melanoma cohort.

Asset / SponsorPhaseRating
Rivoceranib
Peking University Cancer Hospital & Institute
Phase 3B
Endostar
Fudan University
Phase 2CCC
Tuvoraleimab
Fudan University
Phase 2CCC
Toripalimab
Fudan University
Phase 2CCC
Vactosertib
Yonsei University
Phase 2CCC

View all 12 →

Same molecule, other indications

Iparomlimab is also rated in:

HCC - Hepatocellular CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
ES-SCLCDormant
BB
Indicative ·
70 / 100
View asset →
CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →